Published 09/27/2024 4:11:49 p.m.

FDA, after delay, clears Regeneron and Sanofi drug for COPD

Summary by biopharmadive.com

Dupixent is the first biologic medicine approved in the U.S. for the lung condition, though competitors from GSK, AstraZeneca and Roche could follow.

0 Articles

All

Left

Center

Right

STAT

Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD

Market analysts have estimated that the new COPD indication could bring in more than $1 billion in additional annual revenue for Dupixent

09/27/2024 1:56:07 p.m.·Boston, United States

Read Full Article

biopharmadive.com

FDA, after delay, clears Regeneron and Sanofi drug for COPD

Dupixent is the first biologic medicine approved in the U.S. for the lung condition, though competitors from GSK, AstraZeneca and Roche could follow.

09/27/2024 9:35:00 a.m.

Read Full Article

pharmaceutical-technology.com

Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval

The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 monoclonal antibody, Dupixent, for the US market.

09/27/2024 4:11:49 p.m.

Read Full Article

GlobalData

Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market share following FDA approval, says GlobalData

Following the Food and Drug Administration (FDA) approval of Sanofi/Regeneron’s Dupixent (Dupilumab) on 27 September 2024: Asiyah Nawab, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Dupixent, a monoclonal antibody (mAb) targeting interleukin-4 (IL4) and interleukin-13 (IL13) pathways, has been approved by the FDA as the first biologic for uncontrolled chronic obstructive pulmonary disease (COPD), closely …

09/27/2024 3:17:36 p.m.

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center2Last Updated09/28/2024 9:00:20 a.m.Bias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

FDA, after delay, clears Regeneron and Sanofi drug for COPD

0 Articles

0 Articles

Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD

Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD

FDA, after delay, clears Regeneron and Sanofi drug for COPD

FDA, after delay, clears Regeneron and Sanofi drug for COPD

Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval

Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval

Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market share following FDA approval, says GlobalData

Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market share following FDA approval, says GlobalData

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics